SCM
IOVA icon

Sterling Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Sterling Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.4K Sell
8,021
-3,156
-28% -$12K ﹤0.01% 1688
2026
Q1 		$39.2K Sell
11,177
-6,548
-37% -$20.9K ﹤0.01% 1749
2025
Q4 		$48.4K Sell
17,725
-292
-2% -$676 ﹤0.01% 1815
2025
Q3 		$39.1K Buy
18,017
+11,095
+160% +$26.2K ﹤0.01% 1850
2025
Q2 		$11.9K Buy
6,922
+6,625
+2,231% +$16.5K ﹤0.01% 2019
2025
Q1 		$989 Buy
297
+19
+7% +$98 ﹤0.01% 2821
2024
Q4 		$2.06K Buy
278
+17
+7% +$158 ﹤0.01% 2778
2024
Q3 		$2.45K Buy
+261
New +$2.47K ﹤0.01% 2091

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Sterling Capital Management's IOVA Position: Q2 2026 in Review

Sterling Capital Management reduced its Iovance Biotherapeutics (IOVA) stake by 28% in Q2 2026, selling an estimated $12K and leaving 8,021 shares worth $33.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1688.

Sterling Capital Management first reported a position in IOVA in Q3 2024 and has held it in 8 quarters since. The position peaked at $48.4K in Q4 2025. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Sterling Capital Management held 8,021 shares of Iovance Biotherapeutics worth $33.4K as of Q2 2026.
  • Sterling Capital Management sold 3,156 Iovance Biotherapeutics shares in Q2 2026, an estimated $12K.
  • Iovance Biotherapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1688 holding.
  • Sterling Capital Management first reported a position in Iovance Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Iovance Biotherapeutics position peaked at $48.4K in Q4 2025.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.